source
- Life insurers deem active-surveillance prostate cancer 'untreated' and deny term coverage, says patientHoward Wolinsky, a medical journalist, recounts that after his term life policy expired, eight insurers rejected his application because they considered his prostate cancer, managed by active surve…
- AbbVie and Genmab's Epkinly succeeds in late-stage first-line DLBCL trial, challenging Roche's PolivyAbbVie and Genmab announced that their T‑cell engager Epkinly met its primary endpoints in a late‑stage study evaluating first‑line treatment for diffuse large B‑cell lymphoma (DLBCL). The trial de…